Skip to main content

Australia Breaking News

Bloomberg
Financial

Luxury Whiskey Bets on Ready-Made Cocktails

Julie Macklowe, the Founder of the luxury whiskey brand Macklowe, joined Bloomberg Open Interest to talk about how tariffs on liquor ultimately punish American consumers through higher prices, and may even be contributing to younger generations drinking less. She also explains why convenience is driving her latest bet: a premium, ready-to-serve whiskey cocktail designed to make the traditionally "snobby" category more accessible.

Read more: Luxury Whiskey Bets on Ready-Made Cocktails
Bloomberg
Financial

Novartis and Boston Scientific Slide, Intel Price Hikes | Stock Movers

On this episode of Stock Movers: - Novartis (NOVN) shares are lower as it suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study. - Boston Scientific (BSX) shares are moving on news it said that fallout from a cybersecurity incident has impacted its ability to ship its products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year. - Intel (INTC) is rising on a report that the company could raise computer chip prices next month.

Read more: Novartis and Boston Scientific Slide, Intel Price Hikes | Stock Movers
Bloomberg
Financial

Stock Resiliency Depends on Moves by the Fed, Says Principal's Shah

"The next couple of months are likely to be pretty rocky with only modest gains to be had for the rest of the year," says Seema Shah, chief global strategist at Principal Asset Management. Shah says a possible series of hikes by the Federal Reserve can provide some resistance for equities.

Read more: Stock Resiliency Depends on Moves by the Fed, Says Principal's Shah
Bloomberg
Financial

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis's $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker's growth prospects. Fabienne Kinzelmann reports on Bloomberg Television.

Read more: Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback
Bloomberg
Financial

Goldman's Wheeler Says Volume of AI Debt May Pressure Spreads

The sheer volume of AI-related debt issuance could pressure spreads, according to Miriam Wheeler, global head of leveraged finance at Goldman Sachs. "If you look at the last couple weeks in the market on the non-IG [investment grade] side, we have seen some spread widening, particularly in the AI space," Wheeler tells Bloomberg Television.

Read more: Goldman's Wheeler Says Volume of AI Debt May Pressure Spreads